Compare ADMA Biologics Inc (ADMA) vs Norfolk Southern Corporation (NSC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs Norfolk Southern Corporation — how do they compare? ADMA Biologics Inc trades at $9.27 (market cap $2.13B), while Norfolk Southern Corporation trades at $319.48 (market cap $72.49B). The key difference: Norfolk Southern Corporation is far larger — about 34× ADMA Biologics Inc's market cap, and Norfolk Southern Corporation pays a 1.67% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | NSC | |
|---|---|---|
Market Cap | $2.13B | $72.49B |
Sector | Health | Technology |
52-Week High | $20.38 | $325.68 |
52-Week Low | $7.60 | $259.49 |
Enterprise Value | $2.20B | $88.25B |
Dividend Yield | — | 1.67% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
Norfolk Southern (NSC) trades at $321.9, down 0.25% on the day, with a bullish technical outlook supported by moving averages and a consensus analyst price target of $337. The stock shows strong profitability with a 21.91% net income margin and has beaten earnings estimates for three consecutive quarters. Recent news highlights the ongoing merger process with Union Pacific, a key regulatory and operational focus.
The outlook for NSC is cautiously optimistic, with potential upside from the merger and consistent earnings performance, but risks include regulatory hurdles for the merger and rich valuation multiples. Investors should weigh the strong cash flow generation against execution risks in a consolidating industry.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Norfolk Southern Corporation
Norfolk Southern Corporation is a major North American railroad company operating one of the largest freight rail networks in the eastern United States. The company transports a diverse range of commodities, including coal, intermodal containers, and various industrial products. NSC is a critical link in the nation's supply chain, providing efficient, long-haul transportation services to and from ports and industrial centers.
Read more on NSC →
